Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

506
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
506
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

981
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
981
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

569
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
569
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

795
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
795
Urinary Bladder01:23

Urinary Bladder

2.6K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
2.6K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.2K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2005
Same author

Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.

The Journal of steroid biochemistry and molecular biology·2005
Same author

[Extensive, painful erosion of the vulva. Extramammary Paget disease].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2005
Same author

Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours.

European journal of cancer (Oxford, England : 1990)·2004
Same author

In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.

European journal of cancer (Oxford, England : 1990)·2004
Same author

Diagnostic and neural analysis of skin cancer (DANAOS). A multicentre study for collection and computer-aided analysis of data from pigmented skin lesions using digital dermoscopy.

The British journal of dermatology·2003
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Related Experiment Video

Updated: Dec 14, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.2K

[Botulinum toxin for overactive bladder].

B K Ziegelmüller1, A Sommer2, R M Bauer2

  • 1Urologische Klinik und Poliklinik, Klinikum der Ludwig-Maximilians-Universität München, Campus Großhadern, Marchioninistr. 15, 81377, München, Deutschland. Brigitte.Ziegelmueller@med.uni-muenchen.de.

Der Urologe. Ausg. A
|July 22, 2020
PubMed
Summary
This summary is machine-generated.

Idiopathic overactive bladder (OAB) is a condition causing urinary urgency and frequency. For refractory cases, onabotulinum toxin A injections offer a safe and effective treatment option with lasting effects.

Keywords:
ComplicationsDrug therapyIrritable bladderUrge urinary incontinenceUrodynamics

More Related Videos

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.3K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.7K

Related Experiment Videos

Last Updated: Dec 14, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.2K
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.3K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.7K

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Idiopathic overactive bladder (OAB) presents as urinary urgency, frequency, and nocturia without infection or neurological causes.
  • It is a diagnosis of exclusion, often managed with conservative therapies first.
  • Pharmaceuticals are recommended if behavioral therapies fail, following a staged treatment approach.

Purpose of the Study:

  • To evaluate onabotulinum toxin A as a treatment for refractory idiopathic overactive bladder (OAB).
  • To highlight its efficacy, safety, and suitability as a therapeutic option.

Main Methods:

  • Intravesical injection of 100 U onabotulinum toxin A into the detrusor muscle.
  • Treatment administered transurethrally.
  • Repeat injections are permissible without limitations.

Main Results:

  • Onabotulinum toxin A provides a treatment effect lasting an average of 6-9 months.
  • The procedure is associated with a low complication rate.
  • A good success rate is observed in patients with treatment-refractory OAB.

Conclusions:

  • Onabotulinum toxin A is recommended by current guidelines for refractory OAB (Recommendation Level A).
  • Its low invasiveness, good success rate, and low complication profile make it a viable treatment option.
  • Repeated injections can be safely administered, offering sustained management for OAB symptoms.